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ABSTRACT
Purpose When establishing IVIVC, a special problem arises
by interpretation of averaged in vivo profiles insight of consid-
erable individual variations in term of time and number of
mechanical stress events inGI-tract. The objective of the study
was to investigate and forecast the effect of mechanical stress
on in vivo behavior in human of hydrophilic matrix tablets.
Methods Dissolution profiles for the marketed products were
obtained at different conditions (stirring speed, single- or re-
peatable mechanical stress applied) and convoluted into C-t
profiles. Vice versa, published in vivo C-t profiles of the prod-
ucts were deconvoluted into absorption profiles and com-
pared with dissolution profiles by similarity factor.
Results Investigated hydrophilic matrix tablets varied in term
of their resistance against hydrodynamic stress or single stress
during the dissolution. Different scenarios, including repeat-
able mechanical stress, were investigated on mostly prone
Seroquel® XR 50 mg. None of the particular scenarios fits
to the published in vivo C-t profile of Seroquel® XR 50 mg
representing, however, the average of individual profiles relat-
ed to scenarios differing by number, frequency and time of
contraction stress. When different scenarios were combined in
different proportions, the profiles became closer to the original
in vivo profile including a burst between 4 and 5 h, probably,
due to stress-events in GI-tract.
Conclusion For establishing IVIVC of oral dosage forms sus-
ceptible mechanical stress, a comparison of the deconvoluted
individual in vivo profiles with in vitro profiles of different disso-
lution scenarios can be recommended.
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IVIVC In vitro - in vivo correlation
INTRODUCTION
In addition to being used to understand oral bioavailability,
in vitro - in vivo correlation (IVIVC) is being increasingly applied
in the development of controlled release oral dosage forms.
For example, an important and extensive cross-organization
collaborative project involving multidisciplinary partners
(OrBiTo) has examined important physicochemical proper-
ties of active pharmaceutical ingredients, in vitro characteriza-
tion of drug formulations, characterization of in vivo behavior
of compounds and formulations in GI-tract as well as in-silico
models in developing oral dosage forms (1).
Recently, the effect of simulated GI-stress during dissolu-
tion from an extended release matrix tablet has been investi-
gated using a specially adapted dissolution apparatus includ-
ing different load cells (2–8), in-house dissolution testing ap-
paratus (9–11), and periodical loading of dosage forms outside
of the dissolution vessel (12,13). Commonly, a single mechan-
ical stress event e.g. 300 mbar (3,6), 300 g/cm2 (13) or 400 g
(10) during physiologically-relevant dissolution tests was ap-
plied in order to replicate as best as possible in vivo data
obtained with SmartPill® (14). Using an alternative approach,
a “destructive force dependent release system” (15), the max-
imum stomach and small intestine contraction force were
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utilized and determined at the level of approximately 1.9 N
(16) and 1.2 N (17), respectively.
The transportation of tablet along the GI-tract is highly
unpredictable with relatively high intra- and interindividual
variability. Generally agreed periodicity of stomach emptying
via migrating myoelectric is <120 min, however, it is not en-
tirely predictable (18) due to, for example, a retro-propulsion
back into the stomach of non-disintegrated dosage forms (19).
The mechanical stress-events in the stomach and intestine can
depend on many factors including individual physiological
features, type of physical activity, lifestyle, and type of con-
sumed food/drink (20). Also data regarding the effects of tab-
let size on stomach transit are conflicting (21,22). Thus, the
behavior of a non-disintegrating tablet in GI-tract is unique in
terms of residence time in different parts of GI-tract, the effect
of different media, agitation level and number and severity of
stress-events.
The importance of predictive dissolution testing is contin-
uously increasing because of the possibility of pharmacokinetic
modelling and deeper understanding of different factors af-
fecting drug absorption in vivo (23). For this purpose, in vivo
C-t profiles can be deconvoluted to an absorption profile
and then compared to dissolution profiles (24). Because the
dissolution is the rate-determining step for extended release
dosage forms, a correlation of dissolution profile to absorption
profile is justified (25). On another hand, dissolution profiles
can be convoluted into C-t profiles and then compared with
in vivo C-t profiles (24). One problem associated with both
approaches is the relatively high spread on the individual
in vivo data leading to misinterpretation based on averaged
C-t profiles which represent the mean of different scenarios
predetermined by level, number and frequency of the stress
which varies in different parts of the GI-tract (14–17).
Therefore, the comparison of either single or averaged in vivo
with in vitro profiles would be preferable (26). Unfortunately, in
most cases, individual C-t profiles are available only for spon-
sors of bioequivalence trials at fasting conditions, and gener-
ally available data often presents only averaged (geometric
mean) profiles. Only a limited number of available sources
allow an insight into original single C-t profiles and their var-
iability e.g. a bioequivalence study with Seroquel® XR
300 mg (27).
Thus, it appears difficult to fit a specific dissolution scenario
to averaged data. More logically it would be rational to gen-
erate dissolution profiles under different dissolution condi-
tions, which mimic reasonable individual GI scenarios, and
then convert them into predicted individual C-t profiles.
Averaged predicted C-t profiles can be achieved by balancing
of individual profiles in proportions reflecting the probability
of the corresponding scenarios in vivo.
Since swellable/erodible hydrophilic tablets are considered
as highly vulnerable to the mechanical stress, the objective of
this study was to assess the effect of mechanical stress events in
different dissolution scenarios and the impact that may have




Commercial products Tromphyllin® retard 300 mg
(Trommsdorff GmbH & Co. KG, Alsdorf, Germany),
Glucophage® XR 500 mg (Merck Serono GmbH,
Darmstadt, Germany), Alfuzosin-ratiopharm® uno 10 mg
(Ratiopharm GmbH, Ulm, Germany), Seroquel® XR
50 mg (AstraZeneca GmbH, Wedel, Germany) and
Preductal® MR 35 mg (Les Laboratories Servier, Gidy,
France) were used. Chemicals used for preparation of dissolu-
tion media were of Pharmacopoeia grade and used as
received.
Dissolution
Since investigated extended-release hydrophilic matrix tablets
supposed to release most of the active substance in the intes-
tinal environment, USP phosphate buffer solution pH of 6.8
was used as the main dissolution medium. Dissolution testing
was conducted using an USP Apparatus II (28) with a paddle
agitation speed of 50, 100 or 150 rpm (VK 7000, VanKel
Industries, NJ, USA) in 900 mL dissolution medium (29). If
specified, at predetermined time-points (as after 1, 2 and 4 h)
tablets were withdrawn together with 6mL ofmedium, placed
in Petri dishes and subjected to 2 N mechanical loading for
60 s using a texture analyzer (TA.XTplus, Stable Micro
Systems Ltd., UK) equipped with a flat-faced cylindrical
probe with a diameter of 20 mm. After that, tablets were
immediately placed back in the dissolution vessel and residuals
in the Petri dishes were rinsed with 5 mL of medium to con-
tinue the dissolution test. During the dissolution test, samples
were taken at predetermined time-points: for Tromphyllin®
retard 300, Glucophage® XR 500 mg – every 30 min during
the first 6 h and then every hour; Alfuzosin-ratiopharm® uno
10 mg – every 30 min during the first hour and then every
hour; Seroquel® XR 50 mg – at 15, 30, 60, 90, 120 min and
then every hour; and Preductal® MR 35 mg – every 30 min
during the first 7 h and then every hour. The schedule of
mechanical stress loading was the same, but the sampling plan
was for every commercial product individual because of the
different duration and Tmax. Samples were filtered through a
0.22 μm filters and active substances were quantified using
UV-spectroscopy (HP 8453, Agilent Technologies GmbH,
Germany) with following parameters: theophylline - λ =
271 nm, C= 17.62*A, r2 = 0.9993; metformin λ= 234 nm,
C = 14.64*A, r2 = 0.9997, alfuzosin - λ = 245 nm, C =
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9.11*A+ 0.0447, r2 = 0.9998, trimetazidine dihydrochloride
- λ= 269 nm, C = 45.46*A, r2 = 0.9999, quetiapine fumarate
λ= 290 nm, C = 58.14*A, r2 = 0.9999. Drug release (%), pre-
sented as a mean of six parallel measurements, was plotted
versus time.
Deconvolution and Convolution
Published original single dose C-t profile of Glucophage®XR
500 mg (30), Alfuzosin-ratiopharm® uno 10 mg (31),
Tromphyllin® retard 300 mg (31) Preductal® MR 35 mg
(32) and Seroquel® XR 50 mg (31) at fasting conditions have
been shown to follow a one compartmental distributionmodel
and, therefore, deconvoluted using the Wagner-Nelson equa-
tion (Eq. 1) (33, 34) and experimental dissolution profiles were
convoluted into C-t profiles using the following equation (Eq.
2) (33, 34)
where: F is cumulative fraction of drug absorbed at time t; Cp
is the plasma concentration of drug at time t; kel= ln 2/t1/2 is
the elimination rate constant; AUC0- t is the area under the
plasma concentration-time (C-t) profile until time t; D is a dose
corrected on bioavailability; and Vd is apparent volume
distribution.
Profile Comparison
For comparison of profiles the similarity factor (f2) was calcu-
lated using the following equation:







where Cdiss represents data from dissolution profiles achieved
experimentally at different conditions and Cabs. – data from
absorption profiles achieved by deconvolution of published
original profiles.
Similarity factors, for each investigated product, achieved
for dissolution profiles at a different stirring speed vs. absorp-
tion profile were compared with each other by calculation of a
difference between the maximal f2max value in the set and f2i
of interest. The extent and direction of change in dissolution
profiles upon single stress were expressed by a difference be-
tween f2stress and f2no stress. Alternatively, linear regression
analysis was applied to the in vitro–in vivo correlation plots
and the coefficient of determination (r2) was calculated using
the following equation:

















where: xi – fraction dissolved and yi fraction absorbed at re-
spective time points.
RESULTS
For comparison of release and deconvoluted curves, the cor-
relation coefficient (r2), the similarity factor (f2), the mean
dissolution time (MDT) or, for comparison of in vivo and con-
voluted release curves, the AUC are usually used. MDT is an
integral parameter hiding essential information about shape
of dissolution profile. A precise calculation of AUC in this
study was, unfortunately, not possible because the in vivo data
available (only partially) in the literature were used.
Therefore, the correlation coefficient and similarity factor
were applied for comparison of the dissolution and deconvo-
luted in vivo profiles.
Effect of Hydrodynamic Conditions
To investigate the effect of paddle stirring speed, the f2 value
for dissolution profiles at stirring speed 50, 100 and 150 rpm
vs. corresponding absorption profile (deconvoluted published
profiles) were calculated. Drug release from Glucophage®
XR and Preductal® MR was not affected by paddle stirring
speed in the range 50–150 rpm (Fig. 1a and c). The f2 was in a
range 46.6–49.3 and 50.6–57.4 for Glucophage® XR and
Preductal®MR, respectively (Table I). For the discrimination
of existing differences between particular dissolution profiles,
the f2 factor seems to bemore powerful than r2 – coefficient of
determination (Table I), which is, however, mostly used for
quantification of IVIVC (35). A moderate effect of paddle
stirring speed on drug release was observed for Alfuzosin-
ratiopharm® and Tromphyllin® retard (Fig. 1e and g). For
Alfuzosin-ratiopharm®, the f2 increased (47.1, 49.2 and 59.2)
with increasing the stirring speed (50, 100 and 150 rpm), re-
spectively (Table I). For Tromphyllin®, the dissolution profile
at 100 rpm showed the greatest similarity with absorption
profile (f2 = 65.7), followed by dissolution profile at 150 rpm
(f2 = 61.0) and 50 rpm (f2 = 44.3) (Fig. 1g, Table I).
Dissolution profiles of Seroquel® XR demonstrated the
highest discrepancy in release at different paddle stirring speed
(Fig. 1i). The f2 for comparison of dissolution/absorption pro-
files was rather low but increased (21.4, 27.7 and 35.1) with
increasing the stirring speed (50, 100 and 150 rpm), respec-
tively (Table I). Also, the shape of dissolution and absorption
profiles differed considerably. Namely, dissolution profiles
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were continuous, while a pronounced lag time followed by
steep rise was observed on absorption profile (Fig. 1i) which
was derived from a sharp peak at 4.5 h on original in vivo C-t
profile (Fig. 1j).







































Fig. 1 (a, c, e, g and i) Dissolution profiles at stirring speed in phosphate buffer pH 6.8 in comparison with deconvoluted original C-t profiles. (b, d, f, h and j)
convoluted profiles at respective dissolution condition in comparison with original C-t profiles. (a and b) Glucophage® XR 500 mg, (c and d) Preductal® MR
35mg, (e and f) Alfuzosin-ratiopharm® uno 10mg, (g and h) Tromphyllin® retard 300 mg and (i and j) Seroquel® XR 50mg. SD has been waived for clarity of
graphs.
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Effect of Single Mechanical Stress Event
To investigate the effect of a single mechanical stress event on
dissolution, tablets were subjected to 2 N mechanical loading
for 60 s after 1, 2 or 4 h. Under these conditions, dissolution
profiles of Glucophage® XR, Alfuzosin-ratiopharm® and
Tromphyllin® retard demonstrated relatively low changes
(Fig. 2). Accordingly, convoluted C-t profiles had similar
trends, although did not match the original profiles (Fig. 2).
Consequently, f2 values for profiles with single stress events
after 1, 2 and 4 h vs. non-stressed profiles changed only slightly
(Table I).
For Preductal® MR and Seroquel® XR, each individual
stress event caused a burst release. The most pronounced
burst release was after mechanical stress at 4 h (Fig. 2c and
i). Thus, for Preductal® MR, convoluted C-t profile matched
well the original in term of tmax (approx. 4.5 h) unlike Cmax
which was below of original (Fig. 2d). The highest burst release
after 4 h was also in case of Seroquel® XR. The convoluted
C-t profile with applied stress at 4 h was closest to original in
term of Cmax but 1.5–2.5 h delayed (Fig. 2j).
Effect of Repeatable Mechanical Stress Events
Dissolution tests with repeatable mechanical stress events were
performed with Seroquel® XRmatrix tablets since they were
most affected by mechanical stress. The highest f2 value
(59.7%) was obtained using phosphate buffer solution
pH 6.8 at 100 rpm and consequent stress application after 1,
2 and 4 h (Fig. 3a). Due to application of repeatable stress in
the time range 1–4 h, C-t profiles became closer in the shape
to the original (Fig. 3).
Combination of Convoluted C-T Profiles
In order to mimic data aggregation within one bioequivalence
study, profiles according to 5 different in vitro dissolution sce-
narios (Fig. 4, Table II) were convoluted and combined in
different ratios to create weighted averaged C-t profile.
Generally, the shape of these profiles was closer to the original
profile except for the difference in a lag-time (Fig. 4). The lag-
time of the original profiles can be attributed to a gradual
transport of gastric liquid with dissolved drug towards the
small intestine before absorption. This transport was not con-
sidered by direct convolution.
DISCUSSION
All chosen commercial products differ in type and concen-
tration of hypromellose, as a matrix-forming agent, weight,
and shape of the tablets (36). One of the most common
methods to investigate the robustness of swellable/
erodible matrix tablets towards mechanical stress in the
GI-tract can be dissolution testing under increased stirring
speed (37). Generally, the best similarity of absorption and
Table I Similarity Factor (%) Comparing Absorption Profiles with Dissolution Profiles at Different Stirring Speed or Mechanical Stress
Products Stirring speed Mechanical stress
rpm f2 f2max - f2i
* r2 Stress after f2 f2stress - f2no stress
** r2
Glucophage XR 500 mg 50 48.3 1.0 0.990 1 h 47.3 −2.0 0.993
100 49.3 0.0 0.990 2 h 49.2 −0.1 0.993
150 46.6 2.7 0.995 4 h 47.7 −1.6 0.993
Preductal MR 35 mg 50 50.6 6.8 0.988 1 h 63.4 6.2 0.975
100 57.2 0.2 0.987 2 h 67.9 10.7 0.984
150 57.4 0.0 0.987 4 h 56.4 −0.8 0.991
Alfuzosin-ratiopharm uno 10 mg 50 47.1 12.1 0.989 1 h 52.5 3.3 0.989
100 49.2 10.0 0.987 2 h 55.9 6.7 0.991
150 59.2 0.0 0.987 4 h 59.5 10.3 0.990
Tromphyllin retard 300 mg 50 44.3 21.4 0.981 1 h 56.3 −9.4 0.989
100 65.7 0.0 0.992 2 h 59.3 −6.4 0.990
150 61.0 4.7 0.990 4 h 59.6 −6.1 0.990
Seroquel® XR 50 mg 50 21.4 13.7 0.581 1 h 34.6 6.9 0.864
100 27.7 7.4 0.759 2 h 36.8 9.1 0.893
150 35.1 0.0 0.853 4 h 43.9 16.2 0.925
*f2max- f2i – the difference between maximal f2 value in the set and f2 of interest,
**f2stress - f2no stress – the difference between f2 for dissolution at 100 rpm with particular stress and without stress, respectively
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dissolution profiles was at higher stirring speed e.g. 100 or
150 rpm (Table I). General pharmacopeial dissolution test
for tablets with USP Apparatus II recommends stirring
speed 50 rpm, probably, not sufficiently mimicking the
in vivo hydrodynamics which is especially critical for hydro-
philic matrix tablets.
Further source of mechanical stress on dosage forms in the
GI-tract are periodic contractions in stomach and intestine









































Fig. 2 (a, c, e, g and i) Dissolution profiles at 100 rpm in phosphate buffer pH 6.8 and applied stress after 1, 2 or 4 h in comparison with deconvoluted original
C-t profiles. (b, d, f, h and j) convoluted profiles at respective dissolution condition in comparison with the original C-t profile. (a and b) Glucophage® XR
500 mg, (c and d) Preductal® MR 35 mg, E and F) Alfuzosin-ratiopharm® uno 10 mg, (g and h) Tromphyllin® retard 300 mg and (i and j) Seroquel® XR
50 mg. SD has been waived for clarity of graphs.
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with a force of approximately 1.9 N (16) and 1.2 N (17),
respectively. The mechanical stress was applied at 1, 2 and
4 h to cover time range when tablets can be affected by
stomach/pyloric or upper intestinal contractions at fasting
conditions. For some investigated products, namely,
Glucophage® XR, Alfuzosin-ratiopharm® uno and
Tromphyllin® retard dissolutions profiles were almost un-
changed when subjected to 2 N mechanical loading after 1,
2 or 4 h during dissolution test. This robustness was, probably,
the reason for relatively low Tmax variability in vivo (Table III).
Vice versa, for Seroquel® XR and Preductal® MR, the
effect of mechanical stress was considerable being more pro-
nounced when applied late (e.g. 4 h). This is because hydro-
philic matrix tablets become softer upon swelling over time.
Different robustness of investigated products can be explained
by their formulations. Robust formulations contain hypromel-
lose of higher molecular weight and content more than 20%
w/w which allows the formation of gel with sufficient gel
strength at the gel-solution interface over a long time period.
Trying to mimic biorelevant conditions, repeatable me-
chanic stress events need to be considered. This was investi-
gated on the product most susceptible to mechanical stress in
this study, namely, Seroquel® XR. Because of the markable
pH-dependent solubility of quetiapine fumarate, the dissolu-
tion of Seroquel® XR was performed, optionally, in 0.1 N
hydrochloric acid solution in first hour before changed to
phosphate buffer solution pH 6.8. Due to application of re-
peatable stress in the time range 1–4 h, C-t profiles became
closer in the shape to the original (Fig. 3) which was, most
likely, predetermined repeatable stomach and intestinal stress.
Unfortunately, none of the individual dissolution scenarios
described satisfactorily the original profile of Seroquel® XR
50 mg tablets. Therefore, convoluted dissolution profiles
(scenarios) were combined in different proportions, averaged,
and compared with the original C-t profile (Fig. 4, Table II).
a) Dissolution profiles b) C-t profiles
Fig. 3 (a) Dissolution profiles upon consequent stress application after 1, 2 and 4 h during dissolution in 0.1 NHCl and/or phosphate buffer solution pH 6.8 and
stirring speed 50 or 100 rpm in comparison with deconvoluted original C-t profile of Seroquel® XR 50 mg. (b) convoluted profiles at respective dissolution
condition in comparison with the original C-t profile. SD has been waived for clarity of graphs.
Fig. 4 Predicted C-t profiles (weighted geometrical average of different re-
lease scenarios - Table III) in comparison with the original C-t profile of
Seroquel® XR 50 mg.
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The shape of all these profiles was closer to the published
original ones. Some shape similarities, including the burst be-
tween 4 and 5 h, probably, due to stress-events in GI-tract,
were also observed in other bioequivalence trials with
Seroquel® XR tablets - 50 mg (31,40,42), − 200 mg (43)
and - 300 mg (41). However, a perfect matching of burst times
barely possible because in vivo profiles are always representing
the average of particular studies with a limited number of
subjects and very high intra/interindividual variability.
Insight into individual profiles for Seroquel® XR 300 mg
reveals that the burst can occur at 2, 3, 4, 5, 6 or even 10 h
(27). In general, the variations of Tmax in vivo for products
susceptible mechanical stress were more pronounced in com-
parison with stress-resistant e.g. Glucophage®XR (Table III).
Thus, for establishing IVIVC of oral dosage forms susceptible
to mechanical stress, a comparison of the deconvoluted indi-
vidual in vivo profiles with individual in vitro profiles of different
release scenarios would be preferable. Further, a set of in vitro
scenarios in different proportions can be used to achieve av-
eraged profiles.
CONCLUSION
Different marketed products formulated as swellable/
erodible matrix tablets were investigated in terms of
robustness against biorelevant mechanical stress. As ro-
bust formulations, Glucophage® XR 500 mg, Alfuzosin-
ratiopharm® uno 10 mg or Tromphyllin® retard
300 mg were identified. These formulations had rela-
tively low interindividual variability and a correlation
of in vitro profiles generated with conventional dissolu-
tion tests with averaged in vivo profiles can be estab-
lished. For formulations susceptible to mechanical stress
e.g. Seroquel® XR 50 mg, a pharmacopeial dissolution
test at the paddle speeds 50 vs. 150 rpm would give
roughly an insight into robustness of matrix tablets
against gastrointestinal mechanical stress. The IVIVC
would be more successful if deconvoluted individual
in vivo profiles were compared with in vitro profiles gen-
erated with different scenarios of release including the
mechanical stress.
Table II Summary of Dissolution Profiles of Seroquel® XR 50 mg at Different Dissolution Conditions
Dissolution conditions f2, % Scenario
Medium pH Stirring speed, rpm Stress application after
pH 6.8 100 1, 2 and 4 h 59.7 Sc. #1
pH 6.8 100 4 h 43.9 Sc. #2
pH 1 (1 h), pH 6.8 50 1, 2 and 4 h 41.9 Sc. #3
pH 1 (2 h), pH 6.8 50 2 h 40.9 Sc. #4
pH 6.8 100 2 h 36.8 n.a.
pH 6.8 150 no stress 35.8 n.a.
pH 6.8 100 1 h 34.6 n.a.
pH 1 (2 h), pH 6.8 100 2 h 34.3 Sc. #5
pH 1.0 100 1, 2 and 4 h 29.5 n.a.
pH 6.8 100 no stress 27.7 n.a.
n.a. not applied
Similarity factor (f2) compares the dissolution profile under respective conditions and deconvoluted original profile of Seroquel® XR 50 mg
Table III Tmax Variability Sourced from Single-Dose Bioequivalence Trails at Fasten Conditions
API Product Subjects number Tmax (h) ± SD
(range)
Ref.
Metformin hydrochloride Glucophage® XR, 500 mg 18 4.4 ± 0.7 (30)
Glucophage® XR, 750 mg 78 3.8 ± 1.2 (38)
Trimetazidine dihydrochloride Preductal® MR, 35 mg 8 3± 1.5 (32)
24 3.2 ± 1.3 (39)
Quetiapine fumarate Seroquel® XR, 300 mg 24 5.0 (2.5–10) (27)
24 5.0 (0.9–20) (40)
Seroquel® XR, 200 mg 18 5.6 ± 2.0 (41)
Seroquel® XR, 50 mg ≥12 6.0 (31)
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